CN116472278A - 与埃博拉病毒疫苗相关的组合物和方法 - Google Patents

与埃博拉病毒疫苗相关的组合物和方法 Download PDF

Info

Publication number
CN116472278A
CN116472278A CN202180069178.XA CN202180069178A CN116472278A CN 116472278 A CN116472278 A CN 116472278A CN 202180069178 A CN202180069178 A CN 202180069178A CN 116472278 A CN116472278 A CN 116472278A
Authority
CN
China
Prior art keywords
ebola virus
engineered
protein
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180069178.XA
Other languages
English (en)
Chinese (zh)
Inventor
何林玲
朱江
安舒尔·乔杜里
伊恩·威尔逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of CN116472278A publication Critical patent/CN116472278A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/473—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used alpha-Glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180069178.XA 2020-08-10 2021-08-09 与埃博拉病毒疫苗相关的组合物和方法 Pending CN116472278A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063063530P 2020-08-10 2020-08-10
US63/063,530 2020-08-10
PCT/US2021/045178 WO2022035739A2 (en) 2020-08-10 2021-08-09 Compositions and methods related to ebola virusvaccines

Publications (1)

Publication Number Publication Date
CN116472278A true CN116472278A (zh) 2023-07-21

Family

ID=80114705

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180069178.XA Pending CN116472278A (zh) 2020-08-10 2021-08-09 与埃博拉病毒疫苗相关的组合物和方法

Country Status (10)

Country Link
US (2) US11305004B2 (https=)
EP (1) EP4192500A4 (https=)
JP (1) JP7631502B2 (https=)
CN (1) CN116472278A (https=)
AU (1) AU2021324954A1 (https=)
CA (1) CA3190148A1 (https=)
IL (1) IL300527A (https=)
MX (1) MX2023001433A (https=)
WO (1) WO2022035739A2 (https=)
ZA (1) ZA202301221B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024130061A1 (en) * 2022-12-16 2024-06-20 Cz Biohub Sf, Llc Immunogenic ebolavirus fusion proteins and related methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107034225A (zh) * 2017-05-04 2017-08-11 中国人民解放军军事医学科学院生物工程研究所 制备埃博拉病毒糖蛋白与基质蛋白融合突变体的方法
CN110506060A (zh) * 2017-03-30 2019-11-26 昆士兰大学 嵌合分子及其用途
US20190381162A1 (en) * 2016-03-28 2019-12-19 Integrated Biotherapeutics, Inc. Pan filovirus vaccine compositions and methods of making

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211378B2 (en) * 2002-01-31 2007-05-01 Wisconsin Alumni Research Foundation Filovirus vectors and noninfectious filovirus-based particles
GB201502209D0 (en) * 2015-02-10 2015-03-25 Sec Dep For Health The And Chancellor Masters And Scholars Of The University Of Oxford The And Micro Filovirus therapy
WO2016145385A2 (en) 2015-03-11 2016-09-15 Integrated Biotherapeutics, Inc. Pan-ebola and pan-filovirus protective epitopes, antibodies, and antibody cocktails
WO2019241483A1 (en) 2018-06-13 2019-12-19 The Scripps Research Institute Nanoparticle vaccines with novel structural components
CA3107083A1 (en) * 2018-08-13 2020-02-20 Janssen Vaccines & Prevention B.V. Stabilized filovirus glycoprotein trimers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190381162A1 (en) * 2016-03-28 2019-12-19 Integrated Biotherapeutics, Inc. Pan filovirus vaccine compositions and methods of making
CN110506060A (zh) * 2017-03-30 2019-11-26 昆士兰大学 嵌合分子及其用途
CN107034225A (zh) * 2017-05-04 2017-08-11 中国人民解放军军事医学科学院生物工程研究所 制备埃博拉病毒糖蛋白与基质蛋白融合突变体的方法

Also Published As

Publication number Publication date
WO2022035739A3 (en) 2022-03-24
JP7631502B2 (ja) 2025-02-18
US11872277B2 (en) 2024-01-16
US11305004B2 (en) 2022-04-19
US20220040286A1 (en) 2022-02-10
US20220305109A1 (en) 2022-09-29
IL300527A (en) 2023-04-01
CA3190148A1 (en) 2022-02-17
ZA202301221B (en) 2024-05-30
MX2023001433A (es) 2023-03-06
EP4192500A4 (en) 2025-01-01
WO2022035739A2 (en) 2022-02-17
EP4192500A2 (en) 2023-06-14
AU2021324954A1 (en) 2023-02-23
JP2023537518A (ja) 2023-09-01

Similar Documents

Publication Publication Date Title
US12447206B2 (en) Nanoparticle vaccines with novel structural components
US20230190910A1 (en) Scaffolded hiv-1 vaccine immunogens
US20230034467A1 (en) Engineered HCV E2 Immunogens and Related Vaccine Compositions
CN116472278A (zh) 与埃博拉病毒疫苗相关的组合物和方法
JP2023537518A5 (https=)
EA050680B1 (ru) Композиции и способы, связанные с вакцинами против эболавируса
CN121969388A (zh) 新的丙型肝炎病毒（hcv）免疫原及其相关用途
JP2026503111A (ja) 操作されたパラミクソウイルス可溶性融合（ｆ）タンパク質及び関連するワクチン
CN120435313A (zh) 包含新的纳米粒支架的疫苗
EA046652B1 (ru) Вакцины на основе наночастиц с новыми структурными компонентами

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination